Oric Pharmaceuticals (4TZ) Price & Analysis

1 Followers

4TZ Stock Chart & Stats

€10.36

€1.07(11.49%)

At close: Jul 24 4:00 PM EDT

€10.36

€1.07(11.49%)

Day’s Range― - ―

52-Week Range€6.10 - €13.30

Previous CloseN/A

Volume700.00

Average Volume (3M)70.00

Market Cap

€1.23B

Enterprise Value€908.34

Total Cash (Recent Filing)€264.76M

Total Debt (Recent Filing)€3.33M

Price to Earnings (P/E)―

Beta1.16

Next Earnings

Nov 09, 2026

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.35

Shares Outstanding103,652,660

10 Day Avg. Volume70

30 Day Avg. Volume70

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)1.87

Price to Sales (P/S)0.00

P/FCF Ratio-6.30

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€18.48

Price Target Upside78.39% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)-1.3

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthVery low leverage and roughly $381M of equity materially reduce default and refinancing risk for a clinical-stage biotech. This financial flexibility supports continued R&D and multi-year clinical programs, giving the company runway to advance trials without immediate revenue.

Progress To Late-stage Clinical TrialsAdvancing a program to global Phase 3 is a structural de-risking event for a biotech. A registrational trial raises the probability of eventual approval or partnering, diversifies clinical-stage assets, and creates durable value drivers beyond short-term market swings.

Stronger Governance And Compensation FrameworkTighter equity-plan governance and clear shareholder backing improve alignment with investors and reduce managerial discretion over dilution. This enhances long-term governance credibility and helps preserve shareholder value during future financings or strategic transactions.

Bears Say

No Revenues; Widening Net LossesAbsence of product revenue and expanding losses indicate the company remains pre-revenue and dependent on pipeline success. Persistent negative profitability limits internal funding capacity and raises execution risk if clinical outcomes or timelines slip.

Sustained Negative Cash FlowLarge, recurring negative operating and free cash flow mean the business relies on external financing to sustain trials. Even with improved FCF trends, ongoing cash burn increases the likelihood of future equity raises, altering capital structure and planning.

Increased Dilution Capacity From Equity PlansExpanded inducement and equity reserves provide hiring and M&A flexibility but raise structural dilution risk. For a cash-burning, pre-revenue biotech this amplifies shareholder dilution probability when capital is needed to fund late-stage trials or execute deals.

Oric Pharmaceuticals News

Oric Pharmaceuticals price target raised to $27 from $25 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $27 from $25...

17d ago

ORIC

Oric Pharmaceuticals reports Q2 EPS (38c), consensus (36c)

“The recent initiation of Himalayas-1, a global Phase 3 registrational trial, brings us closer to delivering a potentially...

23d ago

ORIC

ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside

In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on Oric Pharmaceuticals, with a...

23d ago

ORIC

Oric Pharmaceuticals Expands Inducement Equity Incentive Plan

Oric Pharmaceuticals ( ($ORIC) ) has shared an update. On July 28, 2026, ORIC Pharmaceuticals’ board approved an...

27d ago

ORIC

Oric Pharmaceuticals initiates Himalayas-1 trial

Oric Pharmaceuticals (ORIC) announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic...

1M ago

ORIC

Oric Shareholders Approve Equity Plan, Governance Measures

Oric Pharmaceuticals ( ($ORIC) ) just unveiled an announcement. On June 18, 2026, ORIC Pharmaceuticals’ shareholders approved an...

2M ago

ORIC

Oric Pharmaceuticals resumed with a Buy at Stifel

Stifel analyst Laura Prendergast resumed coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $14 price target...

3M ago

ORIC

Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained

Oric Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from...

3M ago

ORIC

ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst

Goldman Sachs analyst Corinne Johnson has maintained their bullish stance on ORIC stock, giving a Buy rating on...

3M ago

ORIC

Oric Pharmaceuticals moved to Buy rating at Goldman Sachs

Goldman Sachs moved Oric Pharmaceuticals (ORIC) to a Buy rating and $15 price target from its Early Stage...

3M ago

ORIC

ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts

In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on Oric Pharmaceuticals, with a...

4M ago

ORIC

Oric Pharmaceuticals price target lowered to $16 from $17 at Citi

Citi lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $16 from $17 and keeps a Buy...

4M ago

ORIC

Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)

“The first quarter marked a pivotal step for ORIC as we selected our Phase 3 dose for rinzimetostat,...

4M ago

ORIC

Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR

ORIC Pharmaceuticals (ORIC) “announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research...

4M ago

ORIC

4TZ FAQ

What was Oric Pharmaceuticals’s price range in the past 12 months?

Oric Pharmaceuticals lowest stock price was €6.10 and its highest was €13.30 in the past 12 months.

What is Oric Pharmaceuticals’s market cap?

Oric Pharmaceuticals’s market cap is €1.23B.

When is Oric Pharmaceuticals’s upcoming earnings report date?

Oric Pharmaceuticals’s upcoming earnings report date is Nov 09, 2026 which is in 74 days.

How were Oric Pharmaceuticals’s earnings last quarter?

Oric Pharmaceuticals released its earnings results on Aug 03, 2026. The company reported -€0.328 earnings per share for the quarter, missing the consensus estimate of -€0.31 by -€0.018.

Is Oric Pharmaceuticals overvalued?

According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oric Pharmaceuticals pay dividends?

Oric Pharmaceuticals does not currently pay dividends.

What is Oric Pharmaceuticals’s EPS estimate?

Oric Pharmaceuticals’s EPS estimate is -0.33.

How many shares outstanding does Oric Pharmaceuticals have?

Oric Pharmaceuticals has 103,652,660 shares outstanding.

What happened to Oric Pharmaceuticals’s price movement after its last earnings report?

Oric Pharmaceuticals reported an EPS of -€0.328 in its last earnings report, missing expectations of -€0.31. Following the earnings report the stock price went up 23.37%.

Which hedge fund is a major shareholder of Oric Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:4TZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oric Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

16.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.

Oric Pharmaceuticals (4TZ) Earnings & Revenues

Historic Earnings Reports

4TZ Stock 12 Month Forecast

Average Price Target

€18.48

▲(78.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","24":"€24","9.75":"€9.75","14.5":"€14.5","19.25":"€19.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23.14900161,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€23.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.481095935555558,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€18.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.00318602,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9.75,14.5,19.25,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.85,10.873000123846154,11.896000247692307,12.919000371538461,13.942000495384615,14.96500061923077,15.988000743076924,17.011000866923077,18.03400099076923,19.057001114615385,20.08000123846154,21.103001362307694,22.126001486153847,{"y":23.14900161,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.85,10.513930456581196,11.177860913162393,11.84179136974359,12.505721826324788,13.169652282905982,13.83358273948718,14.497513196068377,15.161443652649574,15.82537410923077,16.489304565811967,17.153235022393165,17.81716547897436,{"y":18.481095935555558,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.85,10.015629693846153,10.181259387692307,10.34688908153846,10.512518775384615,10.678148469230768,10.843778163076923,11.009407856923076,11.17503755076923,11.340667244615384,11.506296938461539,11.671926632307692,11.837556326153846,{"y":12.00318602,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.65,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.986,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.146,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.67,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >